Vivos (RDGL) Cash from Investing Activities (2010 - 2017)

Vivos (RDGL) reported Cash from Investing Activities of $2800.0 for Q1 2017, up 280100.0% sequentially from -$1.0 in Q4 2013.

Vivos (RDGL) Cash from Investing Activities (2010 - 2017) Analysis & Trends

Vivos (RDGL) has 5 years of Cash from Investing Activities data on file, last reported at $2800.0 in Q1 2017.

For the quarter ending Q1 2017, Cash from Investing Activities changed N/A year-over-year to $2800.0; the trailing twelve-month figure through Dec 2017 stood at $2800.0 (changed N/A YoY), and the FY2025 full-year result was -$103185.0, changed N/A from the prior year.
Cash from Investing Activities rose to $2800.0 in Q1 2017, from -$1.0 in the prior quarter.
In the past five years, Cash from Investing Activities ranged from a high of $16789.0 in Q2 2013 to a low of -$24504.0 in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Investing Activities (Qtr)
1	Abbott Laboratories	183.13 Bn	175.83 Bn	6.27 Bn	-20.32 Bn
2	Stryker	128.75 Bn	125.88 Bn	3.81 Bn	-185.00 Mn
3	Medtronic	108.98 Bn	99.76 Bn	6.41 Bn	-917.00 Mn
4	Boston Scientific	68.45 Bn	67.00 Bn	3.61 Bn	-591.00 Mn
5	Edwards Lifesciences	48.01 Bn	44.34 Bn	1.29 Bn	-92.80 Mn
6	GE HealthCare Technologies	28.29 Bn	26.01 Bn	1.98 Bn	-2.50 Bn
7	Dexcom	28.25 Bn	27.13 Bn	750.30 Mn	-298.50 Mn
8	Smith & Nephew	26.91 Bn	26.33 Bn	-	-
9	Koninklijke Philips	25.45 Bn	22.32 Bn	2.07 Bn	-475.32 Mn
10	Vivos	26.71 Mn	25.15 Mn	-3,105.00	-

Download Data